Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
-
Published:2023-12
Issue:
Volume:
Page:
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Spring L.M., Tolaney S.M.ORCID, Fell G., Bossuyt V.ORCID, Abelman R.O.ORCID, Wu B., Maheswaran S., Trippa L., Comander A.ORCID, Mulvey T., McLaughlin S., Ryan P., Ryan L., Abraham E., Rosenstock A., Garrido-Castro A.C.ORCID, Lynce F., Moy B., Isakoff S.J., Tung N., Mittendorf E.A., Ellisen L.W., Bardia A.
Subject
Oncology,Hematology
|
|